Found: 141
Select item for more details and to access through your institution.
Improving an electronic system for measuring PROs in routine oncology practice.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
- Published in:
- Human Vaccines & Immunotherapeutics, 2015, v. 11, n. 10, p. 2469, doi. 10.1080/21645515.2015.1062190
- By:
- Publication type:
- Article
TGF-β signalling-related markers in cancer patients with bone metastasis.
- Published in:
- Biomarkers, 2008, v. 13, n. 2, p. 217, doi. 10.1080/13547500701676019
- By:
- Publication type:
- Article
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
- Published in:
- Epigenetics, 2013, v. 8, n. 9, p. 907, doi. 10.4161/epi.25574
- By:
- Publication type:
- Article
An Intervention to Improve Cancer Patients' Understanding of Early-Phase Clinical Trials.
- Published in:
- IRB: Ethics & Human Research, 2009, v. 31, n. 3, p. 1
- By:
- Publication type:
- Article
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
- Published in:
- Prostate, 2024, v. 84, n. 10, p. 909, doi. 10.1002/pros.24707
- By:
- Publication type:
- Article
Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805.
- Published in:
- Prostate, 2022, v. 82, n. 12, p. 1176, doi. 10.1002/pros.24369
- By:
- Publication type:
- Article
What are survivorship care plans failing to tell men after prostate cancer treatment?
- Published in:
- Prostate, 2021, v. 81, n. 7, p. 398, doi. 10.1002/pros.24116
- By:
- Publication type:
- Article
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial.
- Published in:
- Prostate, 2021, v. 81, n. 6, p. 326, doi. 10.1002/pros.24110
- By:
- Publication type:
- Article
Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
- Published in:
- Prostate, 2020, v. 80, n. 16, p. 1429, doi. 10.1002/pros.24074
- By:
- Publication type:
- Article
Genomic and clinical characterization of pulmonary‐only metastatic prostate cancer: A unique molecular subtype.
- Published in:
- Prostate, 2019, v. 79, n. 13, p. 1572, doi. 10.1002/pros.23881
- By:
- Publication type:
- Article
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU‐AA‐302.
- Published in:
- Prostate, 2019, v. 79, n. 8, p. 929, doi. 10.1002/pros.23798
- By:
- Publication type:
- Article
Risk factors for metastatic prostate cancer: A sentinel event case series.
- Published in:
- Prostate, 2017, v. 77, n. 13, p. 1366, doi. 10.1002/pros.23396
- By:
- Publication type:
- Article
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
- Published in:
- Prostate, 2016, v. 76, n. 13, p. 1218, doi. 10.1002/pros.23209
- By:
- Publication type:
- Article
Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
- Published in:
- Prostate, 2016, v. 76, n. 5, p. 512, doi. 10.1002/pros.23141
- By:
- Publication type:
- Article
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
- Published in:
- Prostate, 2015, v. 75, n. 14, p. 1518, doi. 10.1002/pros.23024
- By:
- Publication type:
- Article
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
- Published in:
- Prostate, 2014, v. 74, n. 15, p. 1560, doi. 10.1002/pros.22874
- By:
- Publication type:
- Article
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
- Published in:
- Prostate, 2014, v. 74, n. 4, p. 433, doi. 10.1002/pros.22765
- By:
- Publication type:
- Article
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
- Published in:
- Prostate, 2012, v. 72, n. 5, p. 487, doi. 10.1002/pros.21449
- By:
- Publication type:
- Article
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: Clinical factors associated with PSA response and disease progression.
- Published in:
- Prostate, 2012, v. 72, n. 4, p. 461, doi. 10.1002/pros.21447
- By:
- Publication type:
- Article
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation.
- Published in:
- Prostate, 2011, v. 71, n. 15, p. 1608, doi. 10.1002/pros.21377
- By:
- Publication type:
- Article
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
- Published in:
- Prostate, 2011, v. 71, n. 4, p. 333, doi. 10.1002/pros.21247
- By:
- Publication type:
- Article
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
- Published in:
- Clinical Genitourinary Cancer, 2023, v. 21, n. 5, p. 546, doi. 10.1016/j.clgc.2023.06.012
- By:
- Publication type:
- Article
Challenges of Conducting Clinical Trials of Natural Products to Combat Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2016, v. 14, n. 6, p. 447
- By:
- Publication type:
- Article
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen‐deprivation therapy.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 3, p. 581
- By:
- Publication type:
- Article
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Identification and characterization of circulating prostate carcinoma cells.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Erratum: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
- Published in:
- 2009
- By:
- Publication type:
- Correction Notice
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
- Published in:
- Nature Medicine, 2009, v. 15, n. 5, p. 559, doi. 10.1038/nm.1944
- By:
- Publication type:
- Article
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).
- Published in:
- Journal of Patient-Reported Outcomes, 2018, v. 2, n. 1, p. N.PAG, doi. 10.1186/s41687-018-0054-5
- By:
- Publication type:
- Article
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study.
- Published in:
- Neuro-Oncology, 2005, v. 7, n. 2, p. 177, doi. 10.1215/S1152851704000183
- By:
- Publication type:
- Article
It's who you know: patient-sharing, quality, and costs of cancer survivorship care.
- Published in:
- Journal of Cancer Survivorship, 2014, v. 8, n. 2, p. 156, doi. 10.1007/s11764-014-0349-3
- By:
- Publication type:
- Article
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
- Published in:
- Cardiovascular Toxicology, 2015, v. 15, n. 4, p. 309, doi. 10.1007/s12012-014-9297-4
- By:
- Publication type:
- Article
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
- Published in:
- Cancer Medicine, 2014, v. 3, n. 5, p. 1322, doi. 10.1002/cam4.289
- By:
- Publication type:
- Article
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology.
- Published in:
- Cancers, 2021, v. 13, n. 10, p. 2304, doi. 10.3390/cancers13102304
- By:
- Publication type:
- Article
Problem Solving to Enhance Clinical Trial Participation Utilizing a Framework- Driven Approach.
- Published in:
- Clinical Advances in Hematology & Oncology, 2020, v. 18, n. 8, p. 468
- By:
- Publication type:
- Article
Preventive care in prostate cancer patients: following diagnosis and for five-year survivors.
- Published in:
- Journal of Cancer Survivorship, 2011, v. 5, n. 3, p. 283, doi. 10.1007/s11764-011-0181-y
- By:
- Publication type:
- Article
Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 22, p. 3994, doi. 10.1002/1878-0261.13314
- By:
- Publication type:
- Article
The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion.
- Published in:
- Molecular Oncology, 2017, v. 11, n. 6, p. 655, doi. 10.1002/1878-0261.12059
- By:
- Publication type:
- Article
Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2010, v. 9, n. 5, p. 297, doi. 10.3816/CCC.2010.n.043
- By:
- Publication type:
- Article
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
- Published in:
- FASEB Journal, 2013, v. 27, n. 10, p. 4279, doi. 10.1096/fj.12-222893
- By:
- Publication type:
- Article
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
- Published in:
- Journal of Translational Medicine, 2010, v. 8, p. 20, doi. 10.1186/1479-5876-8-20
- By:
- Publication type:
- Article
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.
- Published in:
- World Journal of Urology, 2019, v. 37, n. 12, p. 2623, doi. 10.1007/s00345-018-2477-2
- By:
- Publication type:
- Article
A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer.
- Published in:
- Molecular Therapy, 2006, v. 14, n. 1, p. 107, doi. 10.1016/j.ymthe.2006.02.011
- By:
- Publication type:
- Article
Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression.
- Published in:
- PLoS ONE, 2011, v. 6, n. 11, p. 1, doi. 10.1371/journal.pone.0027178
- By:
- Publication type:
- Article
Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor.
- Published in:
- PLoS ONE, 2010, v. 5, n. 6, p. 1, doi. 10.1371/journal.pone.0011208
- By:
- Publication type:
- Article
PURPOSE AND BENEFITS OF EARLY PHASE CANCER TRIALS: WHAT DO ONCOLOGISTS SAY? WHAT DO PATIENTS HEAR?
- Published in:
- Journal of Empirical Research on Human Research Ethics, 2008, v. 3, n. 3, p. 57, doi. 10.1525/jer.2008.3.3.57
- By:
- Publication type:
- Article
Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article